Read by QxMD icon Read

Metastasic bladder cancer

Nick W Liu, Katie S Murray, S Machele Donat, Harry W Herr, Bernard H Bochner, Guido Dalbagni
Purpose: While a definitive cure can be achieved by radical cystectomy and pelvic lymph node dissection in select patients with regional lymphadenopathy, the benefit remains uncertain in patients who present with non-regional metastases. We analyzed the survival outcomes of post-chemotherapy retroperitoneal lymph node dissection. Materials and Methods: We reviewed our institutional database and identified 13 patients with radiographically evident or biopsy proven retroperitoneal nodal metastases with a significant response to chemotherapy...
January 31, 2019: Bladder Cancer
Joost L Boormans, Ellen C Zwarthoff, Peter C Black, Peter J Goebell, Ashish M Kamat, Roman Nawroth, Roland Seiler, Stephen B Williams, Bernd J Schmitz-Dräger
The 16th Meeting of the International Bladder Cancer Network (IBCN) took place from October 11 to 13, 2018 in Rotterdam, the Netherlands. As in the previous year, muscle-invasive bladder cancer (MIBC) was the main topic of the congress based upon the rapid evolution in this field over the last several years. This year´s meeting was dominated by presentations focusing on genomic subtyping in MIBC and identification of novel therapeutic targets. These topics were complemented by submissions on immunotherapy, a variety of clinical topics, and biomarker research...
March 7, 2019: Urologic Oncology
Phillip Marks, Philipp Gild, Armin Soave, Florian Janisch, Sarah Minner, Oliver Engel, Malte W Vetterlein, Shahrokh F Shariat, Guido Sauter, Roland Dahlem, Margit Fisch, Michael Rink
OBJECTIVE: To investigate the impact of variant urothelial carcinoma of the bladder (UCB) histologies on extra nodal extension (ENE) and survival in lymph node (LN) positive bladder cancer patients undergoing radical cystectomy (RC). MATERIAL AND METHODS: We meticulously reviewed all bladder specimens for presence of variant UCB histologies and LN specimen for presence and extent of ENE in 517 UCB patients treated with RC. Descriptive statistics, the Kaplan Meier method and multivariable Cox regression models evaluated the association between variant UCB histology, ENE and survival metrics including disease recurrence-free, cancer-specific, and overall survival, respectively...
March 2019: Surgical Oncology
Nikoletta K Pianou, Petros Z Stavrou, Evangelia Vlontzou, Phivi Rondogianni, Demetrios N Exarhos, Ioannis E Datseris
Prostate cancer (PCa) is the most common solid cancer affecting men worldwide. Serum prostate-specific antigen (PSA) is at present the most commonly used biomarker for PCa screening, as well as a reliable marker of disease recurrence after initial treatment. Bone metastases (BM) are present in advanced stages of the disease. Imaging of BM is important not only for localization and characterization, but also to evaluate their size and number, as well as to follow-up the disease during and after therapy. Bone metastases formation is triggered by cancer initiating cells in the bone marrow and is facilitated by the release of several growth factors...
March 5, 2019: Hellenic Journal of Nuclear Medicine
Toshiki Kijima, Hajime Tanaka, Fumitaka Koga, Hitoshi Masuda, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Yasuhisa Fujii
OBJECTIVES: To evaluate the oncological and functional outcomes associated with selective tetramodal bladder-sparing therapy, comprising maximal transurethral resection of the bladder tumor (TURBT), induction chemoradiotherapy (CRT), and consolidative partial cystectomy (PC) with pelvic lymph node dissection (PLND). MATERIALS AND METHODS: This study analyzed 154 patients with non-metastatic muscle-invasive bladder cancer (MIBC) who were prospectively enrolled into the tetramodal bladder-preservation protocol...
February 27, 2019: BJU International
Michael Chao, Daryl Lim Joon, Vincent Khoo, Sandra Spencer, Huong Ho, Mario Guerrieri, Farshad Foroudi, Damien Bolton
INTRODUCTION: This is a retrospective study conducted to report the tumor control and late toxicity outcomes of patients with intermediate-risk prostate cancer undergoing combination external beam radiation therapy and low dose rate brachytherapy (LDR-PB). METHODS AND MATERIALS: Thirty-one patients received 45 Gray (Gy) of external beam radiation therapy to the prostate and seminal vesicles, together with a brachytherapy boost via a transperineal prostate implant of I125 (108 Gy)...
March 2019: Journal of Medical Imaging and Radiation Sciences
T N Musayev, F A Guliev
AIM: To investigate the rates, types and risk factors for intraoperative complications in patients with bladder cancer undergoing radical cystectomy with various types of urinary diversions. MATERIAL AND METHODS: The study comprised 257 patients, including 241 (93.8%) men and 16 (6.2%) women who underwent radical cystectomy. The mean age of the patients was 58.5 (37-81) years. The analysis included intraoperative blood loss and blood transfusion, the rates of vascular, rectum and nerve injury, and operative time as a function of type of urinary diversion and cystectomy, the type of surgery, tumor stage (pT and pN), body mass index, and the total number of radical cystectomies performed by the surgical team...
October 2018: Urologii︠a︡
Eun Young Kim, Inkeun Park, Young Saing Kim, Hee Kyung Ahn, Hee Young Lee, Jeong Ho Kim
Durvalumab is an immune checkpoint inhibitor that blocks PD-L1. Unlike cytotoxic chemotherapy or molecularly targeted agents, immune checkpoint inhibitors occasionally present distinct response patterns, including radiologic pseudoprogression (initial tumor enlargement with subsequent tumor regression) and immune-related adverse events in normal tissues. We report a case of unusual computed tomography (CT) findings of pseudoprogression of pulmonary metastases in a patient with metastatic bladder cancer after durvalumab treatment: multiple pulmonary metastases turned into ground-glass opacity on first follow-up CT; on second follow-up CT, and after sustained treatment of the PD-L1 inhibitor, the lesion was resolved...
February 7, 2019: Thoracic Cancer
Yujiro Fujie, Kei Adachi, Ryoji Nonaka, Jeong-Ho Moon, Kazuhiko Hashimoto, Shoichiro Fujita, Tadashi Ohnishi
We report a case of advanced sigmoid colon cancer that was resected after chemoradiation therapy(CRT)following ineffective chemotherapy. A 59-year-old woman harbored a lower abdominal tumor the size of an infant's head and was diagnosed with a huge sigmoid colon cancer with invasion to the urinary bladder and metastases to the para-aortic lymph nodes. The patient received 2 courses of modified FOLFOX6(mFOLFOX6)plus cetuximab therapy, which was assessed as ineffective; She then received CRTwith 50.4 Gy in 28 fractions plus concurrent oral S-1(100mg/day for 28 days)...
December 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Di Maria Jiang, Haiyan Jiang, Peter W M Chung, Alexandre R Zlotta, Neil Eric Fleshner, Robert G Bristow, Alejandro Berlin, Girish S Kulkarni, Nimira S Alimohamed, Gregory Lo, Srikala S Sridhar
BACKGROUND: Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy improves survival in muscle-invasive urothelial bladder cancer (MIBC). The use of NAC before chemoradiation (CRT) has been limited, as these patients are often elderly, frail, and ineligible for cisplatin. However, the role of NAC in fit, cisplatin-eligible patients who opt for bladder preservation warrants further evaluation. PATIENTS AND METHODS: Patients with MIBC treated with NAC followed by CRT at the Princess Margaret and Durham Regional cancer centers from 2008 to 2017 were retrospectively reviewed...
February 2019: Clinical Genitourinary Cancer
Peter A van Dam, Yannick Verhoeven, Xuan B Trinh, An Wouters, Filip Lardon, Hans Prenen, Evelien Smits, Marcella Baldewijns, Martin Lammens
Binding between the receptor activator of nuclear factor-kB (RANK) and its ligand (RANKL) triggers recruitment of TNF receptor associated factor (TRAF) adaptor proteins and activation of downstream pathways. RANK/RANKL signaling is controlled by a decoy receptor called osteoprotegerin (OPG) which interacts with RANKL. Additional networks regulating RANK/RANKL signaling are active in a context specific manner. RANK/RANKL signaling is essential for the differentiation of bone-resorbing osteoclasts, and is deregulated in pathological processes such as postmenopausal osteoporosis or cancer induced bone destruction...
January 2019: Critical Reviews in Oncology/hematology
Guido Giordano, Nunzio Olivieri, Mario Rosario D'Andrea, Tania Di Raimo, Erminia Manfrin, Andrea Remo, Massimo Pancione, Matteo Brunelli, Elena De Santis, Giulia Coppola, Aldo Scarpa, Luigi Coppola, Pietro Parcesepe
The eye is a rare site for disseminated malignancies; nevertheless, several tumors may metastasize to ocular structures. Few cases of urothelial and bladder cancer with eye involvement have been described in the literature thus far. The rarity of metastatic ocular localization implies an accurate differential diagnosis among the possible primary tumor sites. However, a specific diagnostic algorithm is not currently available, nor a defined therapeutic approach. Eye metastases are associated with advanced disease and poor prognosis...
January 2019: Oncology Letters
Omar Abdel-Rahman
AIM: This study aims at evaluating the performance of some of the imaging recommendations of the National Comprehensive Cancer Network (NCCN) for initial evaluation of bladder cancer. METHODS: Surveillance, epidemiology and end results program (2010-2015) was queried and patients with clinically (T1-T4) bladder cancer and complete information about clinical T/N (tumor/nodal) stage and metastatic sites were extracted. The following characteristics were evaluated in the current analysis: sensitivity, specificity, number needed to investigate (NNI), positive predictive value (PPV), negative predictive value and accuracy...
January 9, 2019: Journal of Comparative Effectiveness Research
Gang Wang, Chen Zhou, Christopher Conklin, Malcolm M Hayes, Carlos F Villamil, Avrum Ostry, Edward C Jones
Metastatic breast carcinoma to the urinary bladder is rare. Eleven cases of metastatic breast carcinoma to the bladder are described in this report, including one case with a tumor to tumor metastasis. The patients ranged from 51 to 83 years of age. The time intervals between the diagnosis of primary breast cancer and the occurrence of bladder metastases ranged from 41 to 336 months. There were seven cases of invasive ductal carcinoma and four cases of invasive lobular carcinoma. In one case, a lobular carcinoma of the breast metastasized to a concurrent squamous cell carcinoma of the bladder...
January 4, 2019: Virchows Archiv: An International Journal of Pathology
Chao Zhang, Lele Liu, Fang Tao, Xu Guo, Guowei Feng, Feiran Chen, Yao Xu, Lili Li, Xiuxin Han, Vladimir P Baklaushev, Andrey S Bryukhovetskiy, Xin Wang, Guowen Wang
Purpose: Based on a large-population analysis, we aimed to estimate the incidence and survival of bone metastases (BM) in initial bladder cancer (BC) patients and to identify the risk and prognostic factors of BC patients with BM. Patients and methods: Using the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, bladder cancer patients diagnosed between 2010 and 2014 were retrieved. Multivariate logistic and Cox regression analyses were employed to identify risk factors and prognostic factors for BM in BC patients...
2018: Journal of Cancer
Mohammad Abufaraj, Beat Foerster, Eva Schernhammer, Marco Moschini, Shoji Kimura, Melanie R Hassler, Mark A Preston, Pierre I Karakiewicz, Mesut Remzi, Shahrokh F Shariat
CONTEXT: The optimal treatment of urothelial bladder cancer (UBC) with micropapillary (MP) variant histology is not clear. OBJECTIVE: To review the current literature on disease characteristics and treatment outcomes of MP UBC. EVIDENCE ACQUISITION: A systematic search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and the Cochrane Handbook for Systematic Reviews of Interventions...
December 12, 2018: European Urology
Ravit Geva, Juanita Lopez, Sarah Danson, Heikki Joensuu, Avivit Peer, Samuel J Harris, Fabricio Souza, Kaline M C Pereira, Ruth Perets
PURPOSE: Concomitant treatment with radium-223 and paclitaxel is a potential option for cancer patients with bone metastases; however, myelosuppression risk during coadministration is unknown. This phase Ib study in cancer patients with bone metastases evaluated the safety of radium-223 and paclitaxel. METHODS: Eligible patients had solid tumor malignancies with ≥2 bone metastases and were candidates for paclitaxel. Treatment included seven paclitaxel cycles (90 mg/m2 per week intravenously per local standard of care; 3 weeks on/1 week off) plus six radium-223 cycles (55 kBq/kg intravenously; one injection every 4 weeks, starting at paclitaxel cycle 2)...
December 13, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Simone Bersini, Agnes Miermont, Andrea Pavesi, Roger Dale Kamm, Jean Paul Thiery, Matteo Moretti, Giulia Adriani
The reciprocal interaction between circulating tumor cells (CTCs) and tissue-specific cells is influential for the progression of metastases. In particular, the process of extravasation relies on the complex cross-talk between cancer cells and other cellular players such as the endothelium and the secondary tissue. However, most in vitro studies only focus on one heterotypic cell-cell interaction and often lack of physiological relevance. In this project, we investigated both CTC-endothelium and CTC-secondary site interactions during cancer cell extravasation...
November 16, 2018: Oncotarget
Firas Aljabery, Ivan Shabo, Oliver Gimm, Staffan Jahnson, Hans Olsson
PURPOSE: We investigated the effects of alterations in the biological markers p14, p53, p21, and p16 in relation to tumour cell proliferation, T-category, N- category, lymphovascular invasion, and the ability to predict prognosis in patients with muscle-invasive bladder cancer (MIBC) treated with cystectomy and, if applicable, chemotherapy. MATERIALS AND METHODS: We prospectively studied patients with urinary bladder cancer pathological stage pT1 to pT4 treated with cystectomy, pelvic lymph node dissection and postoperative chemotherapy...
December 2018: Urologic Oncology
Shearwood McClelland, Paul H Cooper, Anupama K Acheson, Jeremy N Ciporen, Jerry J Jaboin, Timur Mitin
Introduction: Stereotactic body radiotherapy (SBRT) of the spine has become an increasingly utilized modality in the United States, most commonly for metastatic disease (McClelland et al., 2017). Spinal SBRT in patients with spinal instrumentation has been sparsely examined. We report a patient who developed myelitis following spinal SBRT to a region with existing hardware. Methods: A 55-year-old woman with Stage IV breast cancer developed a T4 vertebral body metastasis and underwent tumor debulking with posteriorly instrumented T3-T5 fusion...
2018: Journal of Radiosurgery and SBRT
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"